Proactive Investors - Run By Investors For Investors

Drug developer Ergomed set to kick off phase II trial on treatment for surgical bleeding

Sales of PeproStat can be as high as US$500mln believes Ergomed
Drug developer Ergomed set to kick off phase II trial on treatment for surgical bleeding
The treatment is designed to staunch heavy bleeding during surgery

Ergomed Plc (LON:ERGO) has begun recruiting for a phase IIb proof-of-concept study on Peprostat to treat a surgical complication called intraoperative bleeding.

A total of 120 people will be enrolled to the trial at 30 centres across in seven European countries. 

Researchers want to assess PeproStat’s ability to control bleeding during surgery in four different procedures - liver, soft tissue, vascular and spinal.

Top line results are expected in the first quarter of next year.

WATCH: Ergomed's Andrew Mackie and Haemostatix's Ben Nichols talk to Proactive's Stocktube about the 'milestone' trial

Ergomed said PeproStat could, potentially be a “disruptive” product in the US$2.5bn market for surgical haemostats. 

Current treatments are limited by a range of issues, including slow onset of action, lack of effect on stronger bleeds and long preparation time.

The Ergomed-developed solution eliminates the risk of exposure to blood derived materials, is more stable allowing the formulation of ready-to-use preparations and has a fast mode of action.

“With these advantages we expect the product to gain significant market share,” the AIM-listed drug developer said.

Chief executive, Dr Miroslav Reljanovic, called the phase II study a “major milestone” following Ergomed’s acquisition of Haemostatix last May in a deal worth an initial £8mln.

"We believe that we have a good chance of obtaining successful results, and with that a compelling data package to advance the product into late stage development and commercial collaboration," said Reljanovic.

Ergomed sees sales potential of up to US$500mln and even if this diluted by partner coming on board at some time, it would be still be transformational for the company added Andrew Mackie, chief business officer.

Shares rose 4% to 190p.


--- Updates with video, line and share price ---

Why Invest In Ergomed Plc? Read More Here

Register here to be notified of future ERGO Company articles
View full ERGO profile View Profile

Ergomed Plc Timeline

April 13 2017

Related Articles

Picture of drugs
July 18 2017
Gross profit in the half year to December was up by 34%
cancer cells
February 10 2017
It has already got £7.2mln of the £14.9mln it is looking to raise, which will help fund the development of two promising cancer drug candidates: RXC004 and RXC005
November 21 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use